Operating Expenses Summary of Transgene SA

Transgene SA's latest annual operating expenses in 2023 was 31.23 Million EUR , up 5.22% from previous year.
Transgene SA's latest quarterly operating expenses in 2024 Q2 was 19.24 Million EUR , down 0.0% from previous quarter.
Transgene SA reported a annual operating expenses of 33.25 Million EUR in annual operating expenses 2022, down -1.44% from previous year.
Transgene SA reported a annual operating expenses of 33.73 Million EUR in annual operating expenses 2021, up 23.55% from previous year.
Transgene SA reported a quarterly operating expenses of 2.65 Million EUR for 2023 Q1, down -85.52% from previous quarter.
Transgene SA reported a quarterly operating expenses of 1.91 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Operating Expenses Chart of Transgene SA (2023 - 1997)

Historical Annual Operating Expenses of Transgene SA (2023 - 1997)

Year	Operating Expenses	Operating Expenses Growth
2023	31.23 Million EUR	5.22%
2022	33.25 Million EUR	-1.44%
2021	33.73 Million EUR	23.55%
2020	27.3 Million EUR	-14.33%
2019	31.87 Million EUR	11.45%
2018	28.6 Million EUR	-6.84%
2017	30.7 Million EUR	17.01%
2016	26.23 Million EUR	-11.74%
2015	29.72 Million EUR	-33.04%
2014	44.39 Million EUR	-1.48%
2013	45.05 Million EUR	-2.16%
2012	46.05 Million EUR	639.7%
2011	6.22 Million EUR	0.48%
2010	6.19 Million EUR	2.03%
2009	6.07 Million EUR	67.25%
2008	3.63 Million EUR	-45.63%
2007	6.67 Million EUR	71.01%
2006	3.9 Million EUR	0.0%
2004	24.18 Million EUR	-0.65%
2003	24.34 Million EUR	8.0%
2002	22.53 Million EUR	-6.02%
2001	23.98 Million EUR	-18.46%
2000	29.41 Million EUR	12.6%
1999	26.11 Million EUR	-3.55%
1998	27.07 Million EUR	19.26%
1997	22.7 Million EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	19.24 Million EUR	0.0%
2023 Q1	2.65 Million EUR	-85.52%
2023 Q4	1.91 Million EUR	0.0%
2023 Q3	1.91 Million EUR	-89.36%
2023 Q2	18.01 Million EUR	579.12%
2023 FY	34.98 Million EUR	5.22%
2022 Q2	20.08 Million EUR	810.63%
2022 Q1	2.2 Million EUR	-89.1%
2022 Q4	18.32 Million EUR	344.73%
2022 FY	33.25 Million EUR	-1.44%
2022 Q3	4.12 Million EUR	-79.49%
2021 Q3	1.53 Million EUR	-91.23%
2021 FY	33.73 Million EUR	23.55%
2021 Q2	17.5 Million EUR	2931.69%
2021 Q4	20.23 Million EUR	1217.81%
2021 Q1	577.5 Thousand EUR	-96.36%
2020 Q1	3.61 Million EUR	-81.35%
2020 Q4	15.86 Million EUR	557.96%
2020 Q3	2.41 Million EUR	-85.18%
2020 Q2	16.26 Million EUR	349.83%
2020 FY	27.3 Million EUR	-14.33%
2019 Q4	19.38 Million EUR	754.15%
2019 Q3	2.26 Million EUR	-86.89%
2019 FY	31.87 Million EUR	11.45%
2019 Q1	1.97 Million EUR	-87.87%
2019 Q2	17.3 Million EUR	778.13%
2018 FY	28.6 Million EUR	-6.84%
2018 Q1	1.65 Million EUR	-72.86%
2018 Q2	1.65 Million EUR	0.0%
2018 Q4	16.25 Million EUR	0.0%
2018 Q3	16.25 Million EUR	882.05%
2017 Q3	6.09 Million EUR	-30.22%
2017 Q1	8.73 Million EUR	45.2%
2017 Q2	8.73 Million EUR	0.0%
2017 FY	30.7 Million EUR	17.01%
2017 Q4	6.09 Million EUR	0.0%
2016 Q2	6.31 Million EUR	0.0%
2016 Q1	6.31 Million EUR	-20.94%
2016 Q3	6.01 Million EUR	-4.75%
2016 FY	26.23 Million EUR	-11.74%
2016 Q4	6.01 Million EUR	0.0%
2015 Q3	7.99 Million EUR	-29.11%
2015 Q2	11.27 Million EUR	0.0%
2015 Q4	7.99 Million EUR	0.0%
2015 FY	29.72 Million EUR	-33.04%
2015 Q1	11.27 Million EUR	24.42%
2014 FY	44.39 Million EUR	-1.48%
2014 Q4	9.06 Million EUR	0.0%
2014 Q3	9.06 Million EUR	-2.79%
2014 Q2	9.32 Million EUR	0.0%
2014 Q1	9.32 Million EUR	-10.28%
2013 Q2	10.68 Million EUR	0.0%
2013 FY	45.05 Million EUR	-2.16%
2013 Q4	10.38 Million EUR	0.0%
2013 Q1	10.68 Million EUR	5.52%
2013 Q3	10.38 Million EUR	-2.81%
2012 Q4	10.12 Million EUR	0.0%
2012 Q3	10.12 Million EUR	0.0%
2012 FY	46.05 Million EUR	639.7%
2011 FY	6.22 Million EUR	0.48%
2010 FY	6.19 Million EUR	2.03%
2009 FY	6.07 Million EUR	67.25%
2008 FY	3.63 Million EUR	-45.63%
2007 FY	6.67 Million EUR	71.01%
2006 FY	3.9 Million EUR	0.0%
2005 Q2	6.01 Million EUR	0.0%
2005 Q1	- EUR	100.0%
2004 Q2	5.68 Million EUR	-9.47%
2004 Q1	6.28 Million EUR	-13.11%
2004 Q3	- EUR	-100.0%
2004 Q4	-24.18 Million EUR	0.0%
2004 FY	24.18 Million EUR	-0.65%
2003 FY	24.34 Million EUR	8.0%
2003 Q4	7.22 Million EUR	37.96%
2003 Q2	5.83 Million EUR	-3.4%
2003 Q3	5.24 Million EUR	-10.14%
2003 Q1	6.03 Million EUR	-6.41%
2002 Q4	6.45 Million EUR	22.44%
2002 FY	22.53 Million EUR	-6.02%
2002 Q1	5.48 Million EUR	-8.1%
2002 Q2	5.32 Million EUR	-2.82%
2002 Q3	5.26 Million EUR	-1.12%
2001 Q3	5.39 Million EUR	-12.44%
2001 Q1	6.44 Million EUR	-5.72%
2001 FY	23.98 Million EUR	-18.46%
2001 Q4	5.96 Million EUR	10.57%
2001 Q2	6.16 Million EUR	-4.35%
2000 Q2	6.05 Million EUR	-22.37%
2000 Q4	6.83 Million EUR	-21.27%
2000 FY	29.41 Million EUR	12.6%
2000 Q3	8.67 Million EUR	43.33%
2000 Q1	7.8 Million EUR	129.86%
1999 Q3	- EUR	0.0%
1999 FY	26.11 Million EUR	-3.55%
1999 Q4	-26.11 Million EUR	0.0%
1999 Q1	- EUR	100.0%
1999 Q2	- EUR	0.0%
1998 FY	27.07 Million EUR	19.26%
1998 Q1	- EUR	0.0%
1998 Q2	- EUR	0.0%
1998 Q3	- EUR	0.0%
1998 Q4	-28.61 Million EUR	0.0%
1997 FY	22.7 Million EUR	0.0%

Peer Operating Expenses Comparison of Transgene SA

Name	Operating Expenses	Operating Expenses Difference
ABIONYX Pharma SA	4.17 Million EUR	-647.69%
ABIVAX Société Anonyme	127.37 Million EUR	75.481%
Adocia SA	15.62 Million EUR	-99.827%
Aelis Farma SA	18.81 Million EUR	-65.955%
Biophytis S.A.	14.33 Million EUR	-117.896%
Advicenne S.A.	8.21 Million EUR	-280.17%
genOway Société anonyme	16.73 Million EUR	-86.584%
IntegraGen SA	5.35 Million EUR	-483.483%
Medesis Pharma S.A.	1.56 Million EUR	-1896.137%
Neovacs S.A.	10.34 Million EUR	-201.937%
NFL Biosciences SA	4.37 Million EUR	-613.957%
Plant Advanced Technologies SA	2.76 Million EUR	-1029.573%
Quantum Genomics Société Anonyme	1.71 Million EUR	-1717.907%
Sensorion SA	27.05 Million EUR	-15.441%
Theranexus Société Anonyme	3 Million EUR	-939.306%
TME Pharma N.V.	5.49 Million EUR	-468.146%
Valbiotis SA	9.86 Million EUR	-216.456%
TheraVet SA	1.64 Million EUR	-1799.334%
Valerio Therapeutics Société anonyme	20.32 Million EUR	-53.696%
DBV Technologies S.A.	89.4 Million EUR	65.068%
Genfit S.A.	54.8 Million EUR	43.013%
GeNeuro SA	14.35 Million EUR	-117.527%
Innate Pharma S.A.	64.57 Million EUR	51.632%
Inventiva S.A.	120.18 Million EUR	74.014%
MaaT Pharma SA	21.59 Million EUR	-44.601%
MedinCell S.A.	32.92 Million EUR	5.136%
Nanobiotix S.A.	58.92 Million EUR	47.001%
OSE Immunotherapeutics SA	23.58 Million EUR	-32.396%
Poxel S.A.	28.76 Million EUR	-8.573%
GenSight Biologics S.A.	32.66 Million EUR	4.375%
Valneva SE	134.92 Million EUR	76.853%

Global Stocks Search

Transgene SA (TNG.PA)

Operating Expenses Summary of Transgene SA

Annual Operating Expenses Chart of Transgene SA (2023 - 1997)

Historical Annual Operating Expenses of Transgene SA (2023 - 1997)

Peer Operating Expenses Comparison of Transgene SA